- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | XOMA Royalty Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 12.06. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 3 | Seeking Alpha | ||
| XOMA ROYALTY CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 12.06. | XOMA Preferred Shares Series A declares $0.539 dividend | 1 | Seeking Alpha | ||
| 12.06. | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | 206 | GlobeNewswire (Europe) | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| 12.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.06.2026 | 1.030 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.06.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.06.2026.ISIN NameAU0000154148 HARTSHEAD... ► Artikel lesen | |
| 23.05. | XOMA Royalty Holdings Corp - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 18.05. | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | 3 | Investing.com Deutsch | ||
| 18.05. | XOMA Royalty Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | XOMA Royalty Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 30.04. | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | 952 | AFX News | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| 30.04. | H.C. Wainwright cuts XOMA stock rating on Ligand acquisition | 4 | Investing.com | ||
| 27.04. | BofA raises Ligand Pharma stock price target on XOMA acquisition | 5 | Investing.com | ||
| 27.04. | BofA hebt Kursziel für Ligand Pharma nach XOMA-Übernahme an | 4 | Investing.com Deutsch | ||
| 27.04. | Stifel erhöht Kursziel für Ligand Pharma nach XOMA-Übernahme | 4 | Investing.com Deutsch | ||
| 27.04. | Stifel raises Ligand Pharma stock price target on XOMA acquisition | 2 | Investing.com | ||
| 27.04. | Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million | 2 | Benzinga.com | ||
| 27.04. | Ligand snaps up fellow biotech royalty aggregator Xoma for $739M | 3 | FiercePharma | ||
| 27.04. | XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday | 1 | Benzinga.com | ||
| 27.04. | Ligand To Acquire XOMA Royalty For Around $739 Mln, Both Stocks Up In Pre-market | 5 | RTTNews | ||
| 27.04. | XFRA X0M: WIEDERAUFNAHME/RESUMPTION | 545 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 108,12 | 0,00 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| BICARA THERAPEUTICS | 26,870 | 0,00 % | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | 0,00 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | 0,00 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | +0,05 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,15 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | 0,00 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | 0,00 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen | |
| QIAGEN | 34,315 | -0,59 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,445 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,720 | 0,00 % | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | ||
| PROKIDNEY | 1,830 | 0,00 % | ProKidney Appoints Kenneth Locke as Chief Technical Officer | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| HUMACYTE | 0,709 | 0,00 % | Humacyte, Inc: Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was... ► Artikel lesen |
Das Unternehmen XOMA ROYALTY CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 25,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA ROYALTY CORPORATION PREF finden Sie auf Wallstreet Online.